WeightWatchers emerges from bankruptcy after slimming down debts
The group filed for bankruptcy in the US in May in order to eliminate 1.15 billion US dollars (£840 million) worth of debt on its balance sheet.
The court process enabled it to restructure its finances and write off the debts, which made up more than 70% of the total amount, while agreeing new terms to pay back its lenders.
WeightWatchers' chief executive Tara Comonte had said it needed to transform amid a 'rapidly evolving weight managing landscape'.
Competition has grown fiercely with demand for prescription weight-loss injections under brand names like Mounjaro and Wegovy growing, while studies into the long-term effects of the jabs are ongoing.
On Tuesday, the group said it had appointed a new chief medical officer, physician Dr Kim Boyd, to lead the integration of emerging science into its wider lifestyle-based offering for members.
Dr Boyd said she planned to expand the company's 'legacy' by 'combining the best tools of modern medicine, like GLP-1s, with science-backed lifestyle change and the power of community to deliver better outcomes'.
GLP-1s, the scientific term for weight-loss jabs, work by reducing food cravings.
WeightWatchers recently partnered with anti-obesity drugs provider CheqUp in the UK so patients taking the medication can access its 'companion' diet and lifestyle support app.
Ms Comonte said it was a 'pivotal moment for the group, adding: 'With renewed financial strength, an expanded leadership team, and the addition of Dr Kim Boyd to lead clinical strategy and programme innovation, we're accelerating our transformation.
'In a landscape dominated by noise, quick fixes, and conflicting advice, WeightWatchers continues to lead as the most trusted, science-backed platform, proven to drive better results and lasting impact.'
The restructuring resulted in the company appointing a new board of directors.
It also revealed it would be launching a new programme later this year to support women through perimenopause, menopause, and postmenopause, through tailored nutritional and behavioural strategies.
The move will help it address a broader gap in healthcare and meet the evolving needs of millions of its members around the world, it said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Guardian
an hour ago
- South Wales Guardian
Watchdog bans host of ads for prescription-only weight-loss medications
The Advertising Standards Authority (ASA) said the nine rulings against the ads – one featuring reality TV personality Gemma Collins – made it 'crystal clear' that all injectable forms of weight-loss medication were prescription-only and therefore could not advertised to the public. In December, the ASA warned businesses and individuals who were targeting members of the public with ads for the medicines. It said no-one operating in the industry could say they had not been warned that weight-loss prescription-only medicines 'must not be promoted to the public'. The ads banned this week include an Instagram post by Collins, posted on January 6, which promoted the weight-loss service Yazen. In a video, Collins stated: 'I'm starting this year two sizes down, thanks to Yazen's weight loss app and medication. It's really quick and easy to get started with Yazen, it has absolutely changed my life… I finally found something that actually I lose weight on.' She continued: 'Yes, there's, you know, reports and stuff. And I'm not telling anyone to go on this medication, but it is prescribed on the NHS.' Two complainants challenged whether the ad breached rules because it promoted prescription-only medication to the public. Yazen said the post had been intended to share information about their 'holistic, responsible approach to weight loss', and had not been intended to focus solely on medication. Following notification of the complaint, and in agreement with Collins, the post has been amended to remove any reference to prescription-only medications. Yazen said they would ensure that future posts were compliant with the advertising code. Collins said she took her responsibilities under the advertising code seriously and strove to comply with them. She accepted that her posts had promoted the Yazen weight-loss service and app, and said Yazen would approve any marketing materials she might post in future, and she would follow any guidance that the ASA provided. The ASA also banned an ad for prescription-only weight-loss medication posted by CheqUp, which read: 'No GP or pharmacy visit, just a 2 minute online consultation.' CheqUp told the ASA that they believed the ad had been created in line with what had become widespread industry practice in the weight-loss sector. They assured the ASA that the ad would not appear again. Other providers who have had their ads banned include Juniper UK, Cloud Pharmacy, and Phlo Clinic and SemaPen. The ASA said the rulings established the advertising of named weight-loss drugs such as Wegovy, Mounjaro, Ozempic and Saxenda was banned, as was the use of various claims such as 'obesity treatment jab' and 'weight loss pen'. In April, the ASA said a search in January found around 1,800 unique paid-for weight-loss ads which were identified as potentially advertising a prescription-only medicine. It has published a joint Enforcement Notice with the Medicines and Healthcare products Regulatory Agency and General Pharmaceutical Council, making clear that ads for named weight-loss prescription-only medications are prohibited, including online, on social media and by influencers.
North Wales Chronicle
2 hours ago
- North Wales Chronicle
Watchdog bans host of ads for prescription-only weight-loss medications
The Advertising Standards Authority (ASA) said the nine rulings against the ads – one featuring reality TV personality Gemma Collins – made it 'crystal clear' that all injectable forms of weight-loss medication were prescription-only and therefore could not advertised to the public. In December, the ASA warned businesses and individuals who were targeting members of the public with ads for the medicines. It said no-one operating in the industry could say they had not been warned that weight-loss prescription-only medicines 'must not be promoted to the public'. The ads banned this week include an Instagram post by Collins, posted on January 6, which promoted the weight-loss service Yazen. In a video, Collins stated: 'I'm starting this year two sizes down, thanks to Yazen's weight loss app and medication. It's really quick and easy to get started with Yazen, it has absolutely changed my life… I finally found something that actually I lose weight on.' She continued: 'Yes, there's, you know, reports and stuff. And I'm not telling anyone to go on this medication, but it is prescribed on the NHS.' Two complainants challenged whether the ad breached rules because it promoted prescription-only medication to the public. Yazen said the post had been intended to share information about their 'holistic, responsible approach to weight loss', and had not been intended to focus solely on medication. Following notification of the complaint, and in agreement with Collins, the post has been amended to remove any reference to prescription-only medications. Yazen said they would ensure that future posts were compliant with the advertising code. Collins said she took her responsibilities under the advertising code seriously and strove to comply with them. She accepted that her posts had promoted the Yazen weight-loss service and app, and said Yazen would approve any marketing materials she might post in future, and she would follow any guidance that the ASA provided. The ASA also banned an ad for prescription-only weight-loss medication posted by CheqUp, which read: 'No GP or pharmacy visit, just a 2 minute online consultation.' CheqUp told the ASA that they believed the ad had been created in line with what had become widespread industry practice in the weight-loss sector. They assured the ASA that the ad would not appear again. Other providers who have had their ads banned include Juniper UK, Cloud Pharmacy, and Phlo Clinic and SemaPen. The ASA said the rulings established the advertising of named weight-loss drugs such as Wegovy, Mounjaro, Ozempic and Saxenda was banned, as was the use of various claims such as 'obesity treatment jab' and 'weight loss pen'. In April, the ASA said a search in January found around 1,800 unique paid-for weight-loss ads which were identified as potentially advertising a prescription-only medicine. It has published a joint Enforcement Notice with the Medicines and Healthcare products Regulatory Agency and General Pharmaceutical Council, making clear that ads for named weight-loss prescription-only medications are prohibited, including online, on social media and by influencers.
Leader Live
2 hours ago
- Leader Live
Watchdog bans host of ads for prescription-only weight-loss medications
The Advertising Standards Authority (ASA) said the nine rulings against the ads – one featuring reality TV personality Gemma Collins – made it 'crystal clear' that all injectable forms of weight-loss medication were prescription-only and therefore could not advertised to the public. In December, the ASA warned businesses and individuals who were targeting members of the public with ads for the medicines. It said no-one operating in the industry could say they had not been warned that weight-loss prescription-only medicines 'must not be promoted to the public'. The ads banned this week include an Instagram post by Collins, posted on January 6, which promoted the weight-loss service Yazen. In a video, Collins stated: 'I'm starting this year two sizes down, thanks to Yazen's weight loss app and medication. It's really quick and easy to get started with Yazen, it has absolutely changed my life… I finally found something that actually I lose weight on.' She continued: 'Yes, there's, you know, reports and stuff. And I'm not telling anyone to go on this medication, but it is prescribed on the NHS.' Two complainants challenged whether the ad breached rules because it promoted prescription-only medication to the public. Yazen said the post had been intended to share information about their 'holistic, responsible approach to weight loss', and had not been intended to focus solely on medication. Following notification of the complaint, and in agreement with Collins, the post has been amended to remove any reference to prescription-only medications. Yazen said they would ensure that future posts were compliant with the advertising code. Collins said she took her responsibilities under the advertising code seriously and strove to comply with them. She accepted that her posts had promoted the Yazen weight-loss service and app, and said Yazen would approve any marketing materials she might post in future, and she would follow any guidance that the ASA provided. The ASA also banned an ad for prescription-only weight-loss medication posted by CheqUp, which read: 'No GP or pharmacy visit, just a 2 minute online consultation.' CheqUp told the ASA that they believed the ad had been created in line with what had become widespread industry practice in the weight-loss sector. They assured the ASA that the ad would not appear again. Other providers who have had their ads banned include Juniper UK, Cloud Pharmacy, and Phlo Clinic and SemaPen. The ASA said the rulings established the advertising of named weight-loss drugs such as Wegovy, Mounjaro, Ozempic and Saxenda was banned, as was the use of various claims such as 'obesity treatment jab' and 'weight loss pen'. In April, the ASA said a search in January found around 1,800 unique paid-for weight-loss ads which were identified as potentially advertising a prescription-only medicine. It has published a joint Enforcement Notice with the Medicines and Healthcare products Regulatory Agency and General Pharmaceutical Council, making clear that ads for named weight-loss prescription-only medications are prohibited, including online, on social media and by influencers.
